Predictive Value of Laboratory, Radiological, and Non-invasive Tests for Liver Biopsy Findings in Treatment-naive, HBeAg-negative Chronic Hepatitis B Patients Tedavi Naif HBeAg-negatif Kronik Hepatit B Hastalarında Karaciğer Biyopsi Bulgularının Öngörülmesinde Laboratuvar, Radyolojik ve Non-invaziv Testlerin Değeri
Namik Kemal Medical Journal, cilt.14, sa.3, ss.252-260, 2026 (ESCI, Scopus, TRDizin)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 14 Sayı: 3
- Basım Tarihi: 2026
- Doi Numarası: 10.4274/nkmj.galenos.2026.70466
- Dergi Adı: Namik Kemal Medical Journal
- Derginin Tarandığı İndeksler: Emerging Sources Citation Index (ESCI), Scopus, TR DİZİN (ULAKBİM)
- Sayfa Sayıları: ss.252-260
- Anahtar Kelimeler: APRI, chronic hepatitis B, KING score, liver biopsy, non-invasive markers
- Sağlık Bilimleri Üniversitesi Adresli: Evet
Özet
Aim: Chronic hepatitis B (CHB) remains a major cause of liver-related morbidity and mortality worldwide. Liver biopsy is considered the reference standard for assessing significant histopathological abnormality (SHA); however, its invasive nature and potential complications limit routine use. This study aimed to evaluate the diagnostic performance of laboratory, radiological, and non-invasive indices in predicting significant histopathological abnormalities in treatment-naïve, HBeAg-negative CHB patients. Materials and Methods: In this retrospective single-center study, adult HBeAg-negative, treatment-naïve CHB patients who underwent liver biopsy between 2010 and 2024 were evaluated. Liver histology was assessed using the Ishak fibrosis score and Knodell histological activity index (HAI). Significant histological activity was defined as HAI ≥6 and/or fibrosis stage ≥2. Several non-invasive indices were calculated. Multivariable logistic regression analyses were performed to identify independent predictors of high HAI and significant fibrosis. Diagnostic performance was assessed using ROC curve analysis. Results: A total of 148 patients were included. Higher hepatitis B virus DNA levels were independently associated with both high HAI [odds ratio (OR): 1.7 per log10 increase, p=0.002] and significant fibrosis (OR: 1.3 per log10 increase, p=0.044). Lower serum albumin levels were independently associated with high HAI (p=0.025). Among non-invasive markers, aspartate aminotransferase to platelet ratio index (APRI), showed the highest accuracy for predicting high HAI [area under the curve (AUC): 0.785; sensitivity 68.2%, specificity 85.0% at a cut-off >0.35]. The KING score demonstrated the best performance for predicting significant fibrosis (AUC: 0.768; sensitivity 61.5%, specificity 87.8%). GUCI and Fibrosis-4 index also showed good discriminatory ability. Conclusion: Simple, routinely available non-invasive indices particularly APRI and KING scores demonstrate good diagnostic performance in identifying SHA in HBeAg-negative CHB patients. These tools may help reduce the need for liver biopsy in selected patients and support clinical decision-making, especially in settings where biopsy access is limited.